Nabla’s CEO Brian Manning asserts independence, ruling out acquisition amid rising AI health competition
Executive summary: Brian Manning was appointed CEO of Nabla, an AI health startup, and publicly declared he is not pursuing acquisition, signaling a commitment to independent growth. This stance differentiates Nabla in a sector where many AI health startups are acquired by big tech, suggesting confidence in its standalone viability and long-term product strategy.
Who is involved: Brian Manning (new CEO), Nabla (AI health startup), potential acquirers (e.g., Google, DeepMind, large health tech firms).
Likely next: Nabla will focus on product development, clinician adoption, and fundraising to scale independently, potentially triggering competitive responses from Big Tech in ambient AI.
Nabla, an AI-powered ambient clinical assistant startup, has appointed Brian Manning as its new CEO, who explicitly stated he is not seeking an acquisition. This signals a strategic shift toward independent growth and product-led scaling in a crowded AI health tech market where incumbents like Google and DeepMind are intensifying their ambitions. Manning’s stance reflects confidence in Nabla’s differentiated technology and traction with clinicians, potentially positioning it as a standalone player in the ambient AI space.
What's next — scenarios
The Independent Scaler (Base Case) (50%)
Nabla maintains its valuation through organic revenue growth and high clinician retention, avoiding M&A premiums.
- Successful Series B or C funding round led by independent VCs
- Public announcement of enterprise-wide contracts with major hospital systems
The Strategic Consolidation (Downside) (30%)
Competitive pressure from Big Tech forces a pivot back to an acquisition exit to secure survival.
- DeepMind launches a direct-to-clinician feature set
- Nabla's cash runway shortens without significant new enterprise ARR
The Category Disruptor (Upside) (20%)
Nabla becomes the industry standard for ambient AI, forcing incumbents to integrate its API rather than compete.
- Integration of Nabla technology into major EMR systems like Epic or Cerner
- Exponential growth in user-generated clinical data sets
The Niche Specialist (Stagnation) (1%)
Nabla remains a viable tool but fails to capture the broader market, limiting growth to boutique practices.
- Low adoption rates in large-scale academic medical centers
What to watch
- Quarterly ARR growth reports through Q4 2024
- Partnership announcements with major Electronic Health Record (EHR) providers in next 90 days
- Key executive hires in Sales or Product development by end of Q4
Timeline
- — ‘I’m not here to be acquired’: Meet Nabla’s new CEO Brian Manning (Sifted — EU startups)
Analysis — what this means
Likely next events
- Nabla to announce new funding round by Q4 2026 to support independent growth
- DeepMind to expand Ambient AI pilots in UK NHS by September 2026
- Nabla to publish clinical efficacy study by November 2026
- Regulatory scrutiny on AI medical device claims to increase in EU by early 2027
Sectors affected
- AI-powered clinical documentation
- Ambient AI in healthcare
- Digital health startups
- AI M&A in medtech
Regulatory implications
- EU AI Act classifies ambient clinical AI as high-risk, requiring conformity assessments by August 2027
- FDA may require real-world performance validation for AI scribes under new draft guidance (expected Q1 2027)
- HIPAA and GDPR compliance scrutiny increasing for ambient listening tools in clinical settings
Historical parallels
- Nuance Communications’ Dragon Medical was acquired by Microsoft in 2021 for $19.7B after dominating ambient clinical AI
- Saykara, an AI ambient scribe startup, was acquired by Amazon in 2020 and later discontinued
- Abridge raised $150M in 2023 and partnered with Epic, avoiding acquisition so far
Key entities
Sources
- ‘I’m not here to be acquired’: Meet Nabla’s new CEO Brian Manning — Sifted — EU startups